HIV patients with psychiatric disorders are less likely to discontinue HAART

AIDS

Volumn 23, Issue 13, 2009, Pages 1735-1742

  Himelhoch, Seth ^a   Brown, Clayton H ^a   Walkup, James ^b   Chander, Geetanjali ^c   Korthius, P Todd ^d   Afful, Joseph ^a   Gebo, Kelly A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

HIV; Psychiatric disorders; Treatment outcomes

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; ETHNICITY; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; OUTPATIENT; PRIORITY JOURNAL; RISK; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEPRESSIVE DISORDER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PATIENT DROPOUTS; RETROSPECTIVE STUDIES;

EID: 69449095967     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832b428f     Document Type: Article

References (35)

1. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-728. (Pubitemid 32717795)
2. Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004; 18 (Suppl 1):S49-S59. (Pubitemid 38365906)
3. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
4. Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004; 5:437-447.
5. Beck EJ, Mandalia S, Williams I, Power A, Newson R, Molesworth A, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of antiretroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS 1999; 13:2157-2164.
6. Baum SE, Morris JT, Gibbons RV, Cooper R. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med 1999; 164:609-612. (Pubitemid 29444319)
7. Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease inhibitor use in clinical practice. J Gen Intern Med 1999; 14:395-401. (Pubitemid 29344614)
8. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13:1763-1769. (Pubitemid 30015725)
9. Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21:1175-1183. (Pubitemid 46763288)
10. Pence BW, Miller WC, Gaynes BN, Eron JJ Jr. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:159-166. (Pubitemid 46292218)
11. Himelhoch S, Treisman G, Moore RA, Gebo K. Does presence of a mental disorder in AIDS patients affect the initiation of anitretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004; 37:1457-1463.
12. Cook JA, Cohen MH, Burke J, Grey D, Anastos K, Kirstein L, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr 2002; 30:401-409. (Pubitemid 34857314)
13. Cournos F, Empfield M, Horwath E, McKinnon K, Meyer I, Schrage H, et al. HIV seroprevalence among patients admitted to two psychiatric hospitals. Am J Psychiatry 1991; 148:1225-1230.
14. Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Dixon LB, Blow FC. Understanding associations between serious mental illness and HIV among patients in the VA Health System. Psychiatr Serv 2007; 58:1165-1172. (Pubitemid 47507955)
15. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31-37. (Pubitemid 32049263)
16. Blank MB, Mandell DS, Aiken L, Hadley TR. Co-occurrence of HIV and serious mental illness among Medicaid recipients. Psychiatr Serv 2002; 53:868-873. (Pubitemid 34742770)
17. Walkup JT, Sambamoorthi U, Crystal S. Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. J Clin Psychiatry 2004; 65:1180-1189.
18. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS 2008; 22:233-243.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-202.
20. Singer JD, Willet JB. It's about time: using discrete-time survival analysis to study duration and the timing of events. J Educ Stat 1993; 18:155-195.
21. Allison PD. Survival analysis using SAS: a practical guide. Cary, NC: SAS Institute Inc.; 1995.
22. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:629-640. (Pubitemid 40973438)
23. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA 2002; 287:203-209. (Pubitemid 34251945)
24. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med 2001; 16:625-633. (Pubitemid 32823894)
25. Yun LWH, Maravi M, Koayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adhernce to antiretorviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr 2005; 38:432-438. (Pubitemid 40381553)
26. Cook JA, Grey D, Burke-Miller J, Cohen MH, Anastos K, Gandhi M, et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in US multisite cohort of HIV-positive women. AIDS Care 2006; 18:93-100. (Pubitemid 41780167)
27. Himelhoch S, Chander G, Fleishman JA, Hellinger J, Gaist P, Gebo KA. Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. Gen Hosp Psychiatry 2007; 29:518-525. (Pubitemid 350088154)
28. Himelhoch S, Powe N, Breaky W, Gebo K. Schizophrenia, AIDS and the decision to prescribe HAART: results of a national survey of HIV clinicians. J Prev Interv Community 2006; 33:109-120. (Pubitemid 46360125)
29. Ohl ME, Landon BE, Cleary PD, LeMaster J. Medical clinic characteristics and access to behavioral health services for persons with HIV. Psychiatr Serv 2008; 59:400-407.
30. Dickerson FB, McNary SW, Brown CH, Kreyenbuhl J, Goldberg RW, Dixon LB. Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. Med Care 2003; 41:560-570.
31. Druss BG, Rosenheck RA. Locus of mental health treatment in an integrated service system. Psychiatr Serv 2000; 51:890-892. (Pubitemid 30456972)
32. Chwastiak LA, Rosenheck RA, Kazis LE. Utilization of primary care by veterans with psychiatric illness in the National Department of Veterans Affairs Healthcare System. J Gen Intern Med 2008; 23:1835-1840.
33. Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:194-201. (Pubitemid 351172186)
34. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40:609-616.
35. Gebo KA, Fleishman JA, Reilly ED, Moore RD. High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States. Med Care 2005; 43:III23-III30.